Sanofi (NASDAQ:SNY) Short Interest Update

Sanofi (NASDAQ:SNY) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 4,560,000 shares, an increase of 23.6% from the May 15th total of 3,690,000 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average daily volume of 2,740,000 shares, the days-to-cover ratio is currently 1.7 days.

Wall Street Analyst Weigh In

SNY has been the subject of a number of recent analyst reports. BNP Paribas initiated coverage on Sanofi in a research note on Tuesday, April 15th. They set an “outperform” rating and a $65.00 price objective for the company. Guggenheim reaffirmed a “buy” rating on shares of Sanofi in a report on Tuesday, June 3rd. Morgan Stanley set a $56.00 target price on Sanofi in a report on Monday, June 2nd. Hsbc Global Res raised Sanofi to a “strong-buy” rating in a report on Monday, April 28th. Finally, The Goldman Sachs Group started coverage on Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 target price on the stock. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $61.50.

Sanofi Trading Down 1.2%

Shares of NASDAQ SNY opened at $47.62 on Thursday. Sanofi has a 12-month low of $45.80 and a 12-month high of $60.12. The company has a market cap of $116.79 billion, a price-to-earnings ratio of 17.01, a price-to-earnings-growth ratio of 0.97 and a beta of 0.50. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The stock’s 50 day simple moving average is $51.35 and its 200 day simple moving average is $52.01.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The business had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. During the same quarter in the previous year, the firm posted $1.78 EPS. The business’s revenue for the quarter was down 11.0% compared to the same quarter last year. Equities research analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were given a dividend of $2.0369 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a yield of 3.1%. This is a positive change from Sanofi’s previous annual dividend of $1.48. Sanofi’s payout ratio is currently 57.14%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SNY. Voya Investment Management LLC grew its stake in shares of Sanofi by 11.6% in the first quarter. Voya Investment Management LLC now owns 206,635 shares of the company’s stock worth $11,460,000 after purchasing an additional 21,540 shares in the last quarter. 1248 Management LLC bought a new stake in shares of Sanofi during the first quarter valued at about $518,000. Modern Wealth Management LLC bought a new stake in shares of Sanofi during the first quarter valued at about $205,000. Intrua Financial LLC bought a new stake in shares of Sanofi during the first quarter valued at about $247,000. Finally, Geneos Wealth Management Inc. raised its stake in shares of Sanofi by 17.2% during the first quarter. Geneos Wealth Management Inc. now owns 11,978 shares of the company’s stock valued at $664,000 after purchasing an additional 1,755 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.